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Pathological expansion of extracellular matrix proteins is
a hallmark of acute and chronic kidney diseases. In both,
matrix accumulation results from an orchestrated overex-
pression of the key profibrotic cytokine transforming
growth factor(TGF)-β and subsequent increases in matrix
protein production and decreases in matrix protein degra-
dation. A critical role of soluble guanylate cyclase (sGC)
and nitric oxide(NO)-dependent cGMP production for
glomerular matrix expansion has recently been docu-
mented in acute anti-thy1 glomerulonephritis, a rat
model of short-term acute, reversible glomerular TGF-β
overexpression and matrix protein accumulation [1]. Sub-
sequently, we have analyzed the renal activity of the NO-
cGMP signaling cascade in and the effect of the specific
sGC stimulator Bay 41-2272 on anti-thy1-induced
chronic glomerulosclerosis (cGS), a long-term rat model
with progressive fibrosis of the whole organ and progres-
sive renal insufficiency [2].
Anti-thy1-induced chronic glomerulosclerosis was
induced injection of anti-thy1 antibody into uni-nephrec-
tomized Wistar rats. One week after disease induction,
animals were randomly assigned to: cGS, cGS plus Bay 41-
2272 (10 mg/kg body weight/d) or cGS plus hydralazine
(15 mg/kg body weight/d).
After 16 weeks of treatment, systolic blood pressure was
comparably decreased by both treatments. In the
untreated cGS animals, expression of sGC mRNA and
NO-stimulated cGMP production was up-regulated in the
tubulointerstitium, while it was decreased in the glomer-
uli. Bay 41-2272 significantly increased glomerular and
tubulointerstitial NO-cGMP signaling. This went along
with marked reductions in glomerular and tubulointersti-
tial matrix accumulation and TGF-beta1 protein expres-
sion. Bay 41-2272 treatment reduced renal cell
proliferation and infiltration with macrophages. In con-
trast, hydralazine did not affect significantly glomerular
and tubulointerstitial NO-cGMP signaling, cell prolifera-
tion and infiltration as well as matrix protein expansion.
In conclusion, expression and activity of soluble guan-
ylate cyclase is markedly up-regulated in tubulointerstitial
fibrosis of anti-thy1-induced chronic renal fibrosis, while
it is reduced in its persisting glomerulosclerosis. Specific
stimulation of sGC signaling by Bay 41-2272 significantly
limits the progressive course of this model towards tubu-
lointerstitial fibrosis and impaired renal function at least
partially in a manner independent of systolic blood pres-
sure. Since progressive renal fibrosis is key to the common
final pathway shared by most, if not all, chronic renal dis-
eases, these novel findings may be well relevant for other
progressive kidney disorders, such as diabetic and hyper-
tensive nephropathy.
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